Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) have been given an average recommendation of “Moderate Buy” by the five ratings firms that are currently covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $43.60.

INO has been the subject of a number of research analyst reports. Oppenheimer decreased their price objective on shares of Inovio Pharmaceuticals from $40.00 to $33.00 and set an “outperform” rating for the company in a report on Monday, August 12th. Royal Bank of Canada lowered their price target on Inovio Pharmaceuticals from $7.00 to $6.00 and set a “sector perform” rating for the company in a report on Friday.

Inovio Pharmaceuticals Trading Down 10.6 %

Shares of NASDAQ INO opened at $4.27 on Friday. Inovio Pharmaceuticals has a fifty-two week low of $4.20 and a fifty-two week high of $14.75. The business’s 50 day moving average price is $5.75 and its 200-day moving average price is $8.17.

Institutional Trading of Inovio Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the stock. Cornercap Investment Counsel Inc. purchased a new position in shares of Inovio Pharmaceuticals in the 2nd quarter worth approximately $184,000. Bank of New York Mellon Corp purchased a new position in Inovio Pharmaceuticals in the second quarter worth $661,000. American Century Companies Inc. grew its holdings in Inovio Pharmaceuticals by 62.2% in the second quarter. American Century Companies Inc. now owns 31,565 shares of the biopharmaceutical company’s stock worth $255,000 after purchasing an additional 12,100 shares during the last quarter. Signature Estate & Investment Advisors LLC acquired a new position in shares of Inovio Pharmaceuticals during the second quarter worth $88,000. Finally, Dimensional Fund Advisors LP purchased a new stake in shares of Inovio Pharmaceuticals during the 2nd quarter valued at $605,000. Hedge funds and other institutional investors own 26.79% of the company’s stock.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.